Intraperitoneal Oncolytic and Tumor Vaccination Therapy with Replication-Competent Recombinant Virus: The Herpes Paradigm

Publisher： Bentham Science Publishers

E-ISSN： 1875-5631|3|2|113-125

ISSN： 1566-5232

Source： Current Gene Therapy, Vol.3, Iss.2, 2003-04, pp. : 113-125

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Oncolytic Herpes Simplex Virus Vectors Fully Retargeted to Tumor- Associated Antigens

By  

Current Cancer Drug Targets, Vol. 18, Iss. 2, 2018-01 ,pp. : 162-170

Bentham Science Publishers

Access to resources Recommend Favorite

Beyond Oncolytic Virotherapy: Replication-Competent Retrovirus Vectors for Selective and Stable Transduction of Tumors

By  

Current Gene Therapy, Vol. 5, Iss. 6, 2005-12 ,pp. : 655-667

Bentham Science Publishers

Access to resources Recommend Favorite

Oncolytic Virus Therapy - Foreword

By  

Current Cancer Drug Targets, Vol. 7, Iss. 2, 2007-03 ,pp. : 123-125

Bentham Science Publishers

Access to resources Recommend Favorite

Non-Engineered, Naturally Oncolytic Herpes Simplex Virus HSV1 HF-10:Applications for Cancer Gene Therapy

By  

Current Gene Therapy, Vol. 8, Iss. 3, 2008-06 ,pp. : 208-221

Bentham Science Publishers

Access to resources Recommend Favorite

Agreement between an in‐house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV‐1 protease, reverse transcriptase, and integrase inhibitors

By  

Journal Of Clinical Laboratory Analysis (Electronic), Vol. 32, Iss. 1, 2018-01 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite